New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists

Christa George; AhYoung Byun; Amanda Howard-Thompson

doi:10.1016/j.amjmed.2018.05.043

New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists

Am J Med. 2018 Nov;131(11):1304-1306. doi: 10.1016/j.amjmed.2018.05.043. Epub 2018 Jul 2.

Authors

Christa George¹, AhYoung Byun², Amanda Howard-Thompson³

Affiliations

¹ Department of Clinical Pharmacy; Department of Family Medicine, University of Tennessee Health Science Center, Memphis. Electronic address: cgeorge1@uthsc.edu.
² Department of Family Medicine, University of Tennessee Health Science Center, Memphis.
³ Department of Clinical Pharmacy; Department of Family Medicine, University of Tennessee Health Science Center, Memphis.

PMID: 29969616
DOI: 10.1016/j.amjmed.2018.05.043

Abstract

The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.

Keywords: GLP-1 combination products; Glucagon like peptide-1 (GLP-1) agonist; Type 2 diabetes.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2 / drug therapy*
Glucagon-Like Peptide 1 / agonists*
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / therapeutic use*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Glucagon-Like Peptide 1